Publication | Closed Access

WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: Identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers

Medicinal ChemistryL-methionine-conjugated Mitoxantrone DerivativeMedicinePharmacologyPathologyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyDrug DiscoveryTopoisomerase Ii InhibitionDrug Resistance